


Antithrombotic drugs and the risk of bloody punctures in regional anesthesia - a retrospective registry analysis

Christine Kubulus ¹, Christine A Gürtesch,¹ Gudrun Wagenpfeil,² Daniel I Sessler,³ Thomas Volk¹

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/rapm-2022-103806>).

¹Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg/Saar, Germany
²Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University, Homburg/Saar, Germany
³Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio, USA; Senior Fellow, Population Health Research Institute, McMaster University, Ontario, Canada

Correspondence to

Dr Christine Kubulus, Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Hospital and Saarland University Faculty of Medicine, 66421 Homburg, Germany; christine.kubulus@uks.eu

Received 16 May 2022
Accepted 22 July 2022
Published Online First
3 August 2022



© American Society of Regional Anesthesia & Pain Medicine 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Kubulus C, Gürtesch CA, Wagenpfeil G, et al. *Reg Anesth Pain Med* 2022;**47**:653–659.

ABSTRACT

Introduction The risk of bleeding during regional anesthesia implementation in patients on antithrombotic therapy remains poorly characterized. We; therefore, analyzed bloody tap rates and adjusted ORs comparing patients who take antithrombotic medications with those who do not.

Methods 65,814 qualifying regional anesthetics (2007–2019) from the Network for Safety in Regional Anesthesia and Acute Pain Therapy registry were included in a retrospective cohort analysis. Procedures in patients who took antithrombotic drugs were compared with procedures in patients who did not. The primary outcome was bloody puncture, defined as any kind of blood aspiration during placement. Secondly, we considered timely discontinuation of thromboprophylaxis and the impact of various drug classes. As a sensitivity analysis, we used propensity matched groups.

Results Patients on antithrombotic therapy were more likely to have a bloody puncture during peripheral nerve block implementation (adjusted OR 1.60; 95% CI 1.33 to 1.93; $p < 0.001$) irrespective of whether therapy was discontinued. In contrast, bloody neuraxial blocks were no more common in patients who took antithrombotic medications (adjusted OR 0.95; 95% CI 0.82 to 1.10; $p = 0.523$) so long as they were paused per guideline. Across both peripheral and neuraxial blocks, concurrent use of more than one platelet and/or coagulation cascade inhibitor nearly doubled the odds (adjusted OR, 1.89; 95% CI 1.48 to 2.40; $p < 0.001$).

Discussion Patients on antithrombotic therapy receiving peripheral blocks are at increased risk for bloody punctures irrespective of discontinuation practice. Patients having neuraxial blocks are not at increased risk so long as antithrombotics are stopped per guidelines. Patients who take combined medications are at especially high risk. Guidelines for discontinuing antithrombotic treatments for neuraxial anesthesia appear to be effective and should possibly be extended to high-risk peripheral blocks.

INTRODUCTION

Regional anesthesia has become increasingly popular both for anesthesia and postoperative analgesia. Although the benefits of regional anesthesia are often apparent, bleeding complications are feared, especially in patients on antithrombotic medications. Given the variety of antithrombotic agents, there remains uncertainty about their

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Relevant bleeding complications in regional anesthesia are rare. Bloody tap may be an initiating event for bleeding complications.

WHAT THIS STUDY ADDS

⇒ Preblock antithrombotic drug use influences the odds of bloody tap as a surrogate indicator.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ These data may influence future guidelines on regional anesthesia and antithrombotic drug use.

perioperative use in patients having regional anesthesia, especially for peripheral blocks.

For neuraxial blocks, there are national and international guidelines that specify how long various antithrombotic medications should be paused before epidural or spinal puncture.^{1–4} Suggestions are available for individual drugs, but not for various combinations. Bleeding complications consequent to peripheral nerve blocks are usually considerably less serious than those that occur during neuraxial blocks, and consequently, peripheral blocks are often performed in anticoagulated patients. Nevertheless, bleeding consequent to peripheral block insertion can cause reversible or persistent sensory and motor deficits, prolonged and complicated hospital stays, need for transfusions, and even death from hemorrhage.^{3 5–7} We currently lack specific guidelines for peripheral regional blocks in patients taking antithrombotic drugs, presumably because there is little evidence on which to base decisions. Consequently, preoperative management of antithrombotic drugs for peripheral blocks is largely based on clinician's assessment of block site compressibility, adjacent vascularity, and the potential consequences of bleeding.^{1–3} Approaches to a more differentiated risk assessment for peripheral nerve and interfascial plane blocks have recently been published by the Canadian Anesthesiologists' Society, and also by the European Society of Anesthesiology and Intensive Care jointly with the European Society of Regional Anesthesia and Pain Medicine.^{3 8}

Vascular puncture can be indicated by blood becoming visible in the needle hump, catheter or syringe. Even if not every bloody puncture may




Figure 1 Flow chart of case selection.

lead to a serious complication,⁸ the risk of a poor neurological outcome in spinal hematoma is almost quadrupled after a bloody tap.⁹ For peripheral blocks, no risk data for a negative outcome after bloody puncture have been described to date. However, it is also evident that most serious complications are described for blocks with a high bloody tap risk such as the psoas compartment block.^{8–10} Given the rarity of clinical meaningful bleeding complications (eg, blood transfusion, surgical revision, paraplegia caused by epidural bleeding, neurological impairment caused by peripheral hematoma), bloody taps are often used as a surrogate parameter for an initiating event. Especially in patients receiving thromboprophylaxis, there are many case reports of bleeding complications.^{5–7, 11} Thus, if intraoperative antithrombotic medications need to be administered and epidural catheter insertion was bloody, guidelines recommended to postpone surgery or to discuss it.^{1, 2} The incidence of vascular punctures is regularly investigated in studies as a variable of interest and it was shown to be influenced by ultrasound guidance^{12–14} and to vary with puncture site^{8, 10} or patients' state of consciousness during regional anesthesia implementation.¹⁵

So far, there are no data showing a direct relationship between antithrombotic therapies and bloody taps in regional anesthesia.

We; therefore, analyzed whether antithrombotic medication influences the odds for a bloody puncture during neuraxial and peripheral regional anesthetic implementation using the Network for Safety in Regional Anesthesia and Acute Pain Therapy registry. Our primary hypothesis was that patients taking antithrombotic drugs are at higher odds of having a bloody puncture than those who do not. Our secondary hypotheses were that the odds of a bloody puncture depends on the timing of antithrombotic interruption, and on the classes of antithrombotic drugs used.

METHODS

Based on the submitted study protocol which included a statistical analysis plan, registry data were released on June 4, 2020, by the Scientific Panel of the network (www.net-ra.eu). This article is consistent with the REporting of studies Conducted using Observational Routinely-collected Data guidance.¹⁶

The Network for Safety in Regional Anesthesia and Acute Pain Therapy was founded in 2007 under the auspices of the German Society for Anaesthesiology and Intensive Care Medicine and the Professional Association of German Anesthesiologists (Nürnberg, Germany). The registry collects perioperative primary data related to regional anesthesia procedures, intravenous patient-controlled analgesia, and combinations thereof.¹⁷ As previously described, each participating hospital uses its own system for documenting regional anesthesia and its acute pain service.^{18, 19} Since the data of the documented treatments are routine data collected directly at the patient's bedside, they are subjected to on-site quality control. Our registry provides clear definitions of how the individual items are to be collected. These are known to the participating hospitals and should be followed. The data are transmitted to the registry in anonymized form. Uploaded data are not automatically checked for completeness since not all fields are required.

Data extraction

We extracted data from 2007 to 2019, a period that included 219,135 regional anesthetics from 26 hospitals. We restricted our analysis to regional anesthetics from centers that contributed at least 100 cases during the specified period. Procedures in patients with non-drug-induced coagulation disorders were excluded. Qualifying procedures were all initially analyzed, and then separately for peripheral and neuraxial blocks (figure 1).

Data integrity was evaluated according to specific rules that identified and deleted incorrectly entered data and identified cases with missing information. We excluded implausible data for sex (ie, male designation excludes obstetrics), age (range 0–119 year according to the registry restriction *year of birth* > 1900), height and weight (range 30–249 cm and 1–249 kg according to the registry restrictions), body mass index (BMI) (range from 12 to 85 kg/m² according to the registry restrictions for height and weight), and creatinine (0–10 mg/dL or <884 μmol/L). Only cases with complete and internally consistent data were used for analysis.

The registry records more than 20 individual antithrombotic drugs which were grouped according to their mechanisms of action into anticoagulants, antiplatelet agents, other antithrombotic drugs, or combinations thereof.

Treating anesthesiologists recorded whether antithrombotic medications were discontinued in a timely manner or did not need to be discontinued, based on current national guidelines.^{4, 20} Low-dose aspirin was normally continued in accordance with the guideline because a substantive increase in bleeding risk was not expected.^{21, 22}

For peripheral blocks, there is a single national guideline published in 2005 by the German Society for Anaesthesiology and Intensive Care Medicine.²⁰ It recommends that psoas compartment blocks be handled the same way as epidural blocks. We thus considered psoas compartment blocks to be neuraxial procedures, along with spinal and epidural blocks. For other peripheral and plexus blocks, there is no specific guidance in Germany. Peripheral blocks, however, have been mentioned in international guidelines during the observation period.^{1, 2} Designation to the two groups 'paused adequately long' or 'not paused adequately long' was therefore a clinical decision by the attending anesthesiologist, presumably based on whether coagulation was thought to remain unimpaired.

For neuraxial blocks, the German national guideline is largely consistent with international guidelines and contains detailed suggestions for discontinuation of all available antiplatelet and

anticoagulant drugs.⁴ When drugs were discontinued at or before the recommended times, cases were designated as having been ‘paused per guideline’. We assumed that both antithrombotic therapies ‘not paused’ and ‘allowed to continue’ would ultimately result in impaired clotting. Both designations were therefore combined into ‘not paused per guideline’.

The Network for Safety in Regional Anesthesia and Acute Pain Therapy registry defines a bloody puncture as any blood aspiration through the needle or catheter during regional anesthesia placement. The dichotomous occurrence of a bloody puncture (yes or no) was predefined as our primary event.

Statistical analysis

The primary and secondary analyses complied with the a priori statistical analysis plan that was included in the study protocol submitted to the registry before data were released to the investigators. We predefined potential confounding factors for our primary and secondary analyses including year of surgery, sex, age, BMI, American Society of Anesthesiologists physical status, renal insufficiency, use of sedative drugs or general anesthesia during block performance, puncture site, catheter use versus single shot approach, multiple skin punctures, and use of ultrasound.

For the primary analysis, we identified cases with a documented use of antithrombotic drugs prior to the regional anesthetic block and a reference group without thromboprophylaxis. Our primary outcome was the odds of having a bloody puncture, adjusted for the confounders mentioned above. We initially evaluated the adjusted odds across all documented regional anesthesia procedures, and then separately for peripheral and neuraxial approaches.

Our secondary analysis explored the impact of a guideline-driven pause of antithrombotic therapy on the adjusted odds for bloody punctures. We categorized cases with platelet inhibitor and/or anticoagulant therapy into therapy ‘paused per guideline/paused adequately long’ or ‘not paused per guideline/not paused adequately long’ and compared each group to cases in which antithrombotic medications were not used. We also performed a direct comparison of the two groups ‘paused per guideline/paused adequately long’ and ‘not paused per guideline/not paused adequately long’. Additionally, we analyzed the adjusted odds of a bloody puncture with various groups of antithrombotic drugs. Cases were grouped into antiplatelet agents, anticoagulant agents, others, and combined antiplatelet and/or anticoagulant agents, with each being compared with patients who did not take antithrombotic medications. As in our primary analysis, we initially evaluated all regional anesthesia procedures together, followed by independent analyses of peripheral and neuraxial blocks.

We used multivariable logistic regression models for our primary and secondary analyses. Associations were tested using a Wald-type test with 5% type-1-error rate and reported as ORs with 95% CIs. Hosmer-Lemeshow tests evaluated model fit. Testing for multicollinearity showed that variance inflation factors for independent variables were all <1.75. Statistical evaluation was performed using IBM SPSS Statistics V.26 (IBM, USA). Two-sided *p* values less than 0.05 were considered statistically significant.

We planned to include all qualifying procedures. But we nonetheless conducted a priori sample size estimates to assess practicality of evaluating our primary outcome using PASS 2019 (NCSS, USA). We estimated that 29 612 patients would provide 80% power at a 0.050 significance level (OR 1.2 and R-squared

0.8) in a logistic regression model (assuming 20% of patients took antithrombotic drugs). As the registry contained more than 200 000 cases within the predefined period, the study was considered feasible.

In a post hoc sensitivity analysis, propensity scores were estimated via logistic regression using all potential confounders. Matched pairs were created using nearest neighbor 1–1 matching on the propensity score with caliper 0.1*SD(PS) without replacement via R package ‘MatchIt’ V.4.3.3. Using the matched data sets for all regional anesthetic procedures, only peripheral, and neuraxial blocks, the treatment effect was estimated by univariable conditional logistic regression analysis and doubly robust adjustment.²³

Differences in baseline characteristics are expressed as absolute standardized differences, with values <0.1 considered well balanced. Categorical variables are expressed as absolute frequencies and percentages, χ^2 tests were performed to evaluate group differences. Numeric variables (age, BMI) are reported as means and SDs. Group differences were evaluated with Mann-Whitney U tests since variables were not normally distributed.

RESULTS

We considered 219,135 regional anesthesia procedures, but three-quarters were excluded because of missing data, leaving 65,814 for analysis (figure 1). Demographic characteristics and distributions of the clinical and procedural variables for our primary analysis are shown in table 1 (full data available in online supplemental file 1).

There were 34 685 peripheral blocks; 27% of the procedures were done in patients taking anticoagulant and/or antiplatelet drugs. The odds of a bloody puncture was 60% higher when patients took antithrombotic drugs prior to block implementation (table 2, figure 2, >99% power at a 0.050 significance level). A total of 8832 peripheral blocks provided information about discontinuation of the antithrombotic medication of which therapy was judged to be paused adequately in 85%. Antithrombotic therapy strongly increased the odds for a bloody puncture, regardless of whether it was paused per guidelines or not (table 3, figure 2). A total of 9374 peripheral blocks provided information about the drugs used (9% antiplatelet drugs, 82% anticoagulants, 9% combined therapies). After confounder adjustment, the odds for a bloody puncture was increased by 67% for anticoagulants, but not for antiplatelet drugs, and more than doubled for combined therapies (table 4, figure 2, 83% power at a 0.050 significance level).

There were 31,129 neuraxial blocks of which 37% of the procedures were done in patients taking anticoagulant and/or antiplatelet drugs. After confounder adjustment, antithrombotic drugs did not increase the odds of a bloody puncture (table 2, figure 2)—presumably because most were stopped per guidelines. A total of 11,116 neuraxial blocks provided information about discontinuation of the antithrombotic medication, of which therapy was paused per guideline in 89%. Antithrombotic therapy prior to the regional anesthetic block, when paused per guideline, did not increase the odds of a bloody puncture even compared with cases with no antithrombotic therapy (table 3, figure 2). When therapy was not paused per guideline, the odds compared with a guideline-led therapy interruption was significantly increased (table 3, 76% power at a 0.050 significance level), although there was no significant increase compared with cases without antithrombotic therapy (table 3, figure 2). A total of 11,616 neuraxial blocks provided information about the antithrombotic drugs used (7% antiplatelet drugs,

Table 1 Demographic and procedural data

	Patients with thromboprophylaxis	Patients without thromboprophylaxis	P value* †
Sample size, n	21,009	44,805	
Demographic data			
Female sex, n (%)	10,162 (48)	23,830 (53)	<0.001
Mean age (SD) in years	64.0 (15)	58.4 (18)	<0.001
Mean BMI (SD) in kg/m ²	28.2 (6)	28.1 (6)	<0.01
ASA status, n (%)			
ASA 1	1475 (7)	5931 (13)	<0.001
ASA 2	7900 (38)	21,938 (49)	
ASA 3	10,897 (52)	16,349 (37)	
ASA ≥4	737 (4)	587 (1)	
Mean year of surgery (SD)	2012 (3)	2014 (3)	<0.001
Renal insufficiency‡, n (%)	5715 (27)	7244 (16)	<0.001
Procedural data			
Peripheral puncture site, n (%)	9386 (45)	25,299 (57)	<0.001
Neuraxial puncture site, n (%)	11,623 (55)	19,506 (44)	
Awake during block placement, n (%)	9915 (47)	17,949 (40)	<0.001
Sedated/general anesthesia, n (%)	11,094 (53)	26,856 (60)	
Single shot, n (%)	3792 (18)	10,807 (24)	<0.001
Catheter, n (%)	17,217 (82)	33,998 (76)	
Use of ultrasound, n (%)	4221 (20)	15,682 (35)	<0.001
Multiple skin puncture, n (%)	3797 (18)	5742 (13)	<0.001
Bloody tap	626 (3.0)	909 (2.0)	<0.001

*P value compares patients with thromboprophylaxis versus patients without thromboprophylaxis.
†Mann-Whitney U test used to compare means and χ^2 test used to compare proportions.
‡Defined as dialysis or CKD EPI < 60 mL/min/1.73 m².
ASA, American Society of Anesthesiologists; BMI, body mass index; CKD EPI, Chronic Kidney Disease Epidemiology Collaboration estimating equation for eGFR.

85% anticoagulants and 8% were combinations thereof). After confounder adjustment, the odds for a bloody puncture during neuraxial block placement was 77% higher in patients with a combined antithrombotic therapy (table 4, figure 2, 92% power at a 0.050 significance level). The single use of an antiplatelet or anticoagulant drug, mostly stopped per guidelines, did not significantly increase the odds for a bloody puncture.

Sensitivity analysis

Matching resulted in 8220 pairs for peripheral blocks and 9852 pairs for neuraxial blocks. Online supplemental file 1 shows the distribution of variables in the original and matched data sets. After matching, the groups were comparable with respect to covariate balance (absolute SD<0.1 for all variables). Within

the propensity matched sample across peripheral blocks, the odds increased about 50% with antithrombotic drugs (OR 1.48; 95% CI 1.19 to 1.82; p<0.001). In contrast, for neuraxial blocks, the odds were unchanged (OR 1.0; 95% CI 0.85 to 1.18; p=0.994, full data available in online supplemental file 2). Results of our propensity-matched sensitivity analysis were therefore similar to those obtained with multivariable regression.

DISCUSSION

The incidence of bloody punctures in our patients was well within the range previously reported which is from 0.9% to 4.4% for peripheral blocks,^{15 24–26} and from 0.5% to 3% for neuraxial blocks.^{15 24 27} Fortunately, most bloody punctures do not lead to serious complications, but some do.^{8 9} For peripheral blocks,

Table 2 Primary outcome: risk of bloody punctures in patients with and without thromboprophylaxis

	Patients with thromboprophylaxis*	Patients without thromboprophylaxis	P value†
Peripheral blocks			
Group size/no of bloody taps (%)	9386/277/3.0	25,299/318/1.3	<0.001‡
Crude OR (95% CI)	2.39 (2.03 to 2.81)	1	<0.001
Adjusted§ OR (95% CI)	1.60 (1.33 to 1.93)	1	<0.001
Neuraxial blocks			
Group size/no of bloody taps (%)	11,623/349/3.0	19,506/591/3.0	0.892‡
Crude OR (95% CI)	0.99 (0.87 to 1.13)	1	0.892
Adjusted§ OR (95% CI)	0.95 (0.82 to 1.10)	1	0.523

*Any kind of antithrombotic medication before regional anesthesia block implementation.
†P value compares patients with thromboprophylaxis to patients without.
‡ χ^2 test used to compare proportions.
§Adjusted for year of surgery, sex, age, body mass index, American Society of Anesthesiologists physical status, use of sedative drugs or general anesthesia during block performance, catheter use versus single shot approach, multiple skin punctures, and use of ultrasound.




Figure 2 Odds for bloody punctures posed by antithrombotic therapy in regional anesthesia. *Adjusted for year of surgery, sex, age, body mass index, American Society of Anesthesiologists physical status, renal insufficiency, use of sedative drugs or general anesthesia during block performance, catheter use vs single shot approach, multiple skin punctures, and use of ultrasound. Comparator: patients without antithrombotic therapy.

the incidence was higher in patients who had an antithrombotic therapy than in those who did not (3% vs 1.3%). Our results are therefore consistent with the logical assumption that antithrombotic therapy can promote bleeding which is supported by many case reports.^{5–7 11}

Bloody punctures range from a blood tinged aspirate to brisk bleeding whereas a vascular puncture may remain undetected. We believe that bloody punctures are underreported in clinical routine because the threshold for documenting remains

subjective. Since the only objectively conceivable quantification would be an erythrocyte count, almost all publications use a pragmatic approach without exact definition.^{28 29} Extrapolation of a surrogate maker such as bloody tap to extremely rare events such as epidural hematoma is not possible even with the large case numbers available in the NET-RA registry at this time. Given the rarity of clinically meaningful bleeding complications, we nevertheless consider it justified to use bloody puncture as a surrogate parameter for an initiating event and

Table 3 Secondary outcomes: risk of bloody punctures in relation to a pause of antithrombotic drugs

	Controls without antithrombotic drugs	Antithrombotic drugs paused*	P value	Antithrombotic drugs not paused	P value
Peripheral blocks					
Group size/no of bloody taps (%)	25,299/318 (1.3)	7502/232 (3.1)	<0.001	1330/35 (2.6)	<0.001
Crude OR (95% CI)	1	2.51 (2.11 to 2.98)†	<0.001	2.12 (1.49 to 3.02)†	<0.001
Adjusted‡ OR (95% CI)	1	1.65 (1.35 to 2.01)†	<0.001	1.63 (1.13 to 2.35)†	<0.01
Crude OR (95% CI)	1	1		0.85 (0.59 to 1.21)§	0.366
Adjusted‡ OR (95% CI)	1	1		1.0 (0.67 to 1.48)§	0.997
Neuraxial blocks					
Group size/no of bloody taps (%)	19,506/591 (3.0)	9872/269 (2.7)	0.143	1244/53 (4.3)	0.015
Crude OR (95% CI)	1	0.90 (0.78 to 1.04)†	0.143	1.42 (1.07 to 1.90)†	0.016
Adjusted‡ OR (95% CI)	1	0.86 (0.73 to 1.01)†	0.059	1.19 (0.88 to 1.60)†	0.252
Crude OR (95% CI)	1	1		1.59 (1.18 to 2.15)§	<0.01
Adjusted‡ OR (95% CI)	1	1		1.42 (1.03 to 1.97)§	0.033

*Paused was defined as a guideline-driven pause in neuraxial blocks and a pause judged adequate by the treating anesthetist in peripheral blocks.

†Compares patients on antithrombotic medications (paused, respectively, not paused) with controls.

‡Adjusted for year of surgery, sex, age, body mass index, American Society of Anesthesiologists physical status, use of sedative drugs or general anesthesia during block performance, catheter use versus single shot approach, multiple skin punctures, and use of ultrasound.

§Direct comparison of patients in whom antithrombotic medications were paused as defined and of patients without adequate pause.

Table 4 Secondary outcomes: risk of bloody punctures with regard to different antithrombotic drug classes

	Controls without antithrombotics	Antiplatelet drugs	P value*	Anticoagulant drugs	P value*	Combined therapy†	P value*
Peripheral blocks							
Group size/no of bloody taps (%)	25,299/318 (1.3)	855/11 (1.3)	0.939‡	7667/236 (3.1)	<0.001‡	852/30 (3.5)	<0.001‡
Crude OR (95% CI)	1	1.02 (0.56 to 1.89)	0.339	2.50 (2.10 to 2.96)	<0.001	2.87 (1.96 to 4.20)	<0.001
Adjusted§ OR (95% CI)	1	0.76 (0.41 to 1.40)	0.372	1.67 (1.37 to 2.04)	<0.001	2.11 (1.41 to 3.16)	<0.001
Neuraxial blocks							
Group size/no of bloody taps (%)	19,506/591 (3.0)	788/35 (4.4)	0.025‡	9871/262 (2.7)	0.070‡	957/52 (5.4)	<0.001‡
Crude OR (95% CI)	1	1.49 (1.05 to 2.11)	0.026	0.87 (0.75 to 1.01)	0.070	1.84 (1.37 to 2.46)	<0.001
Adjusted§ OR (95% CI)	1	1.18 (0.80 to 1.68)	0.374	0.85 (0.72 to 1.00)	0.047	1.77 (1.31 to 2.40)	<0.001

*P value compares patients with antiplatelet, anticoagulant or a combined therapy to controls without antithrombotic medication.
†Combination of more than one antiplatelet and/or anticoagulant drug.
‡ χ^2 test used to compare proportions.
§Adjusted for year of surgery, sex, age, body mass index, American Society of Anesthesiologists physical status, use of sedative drugs or general anesthesia during block performance, catheter use versus single shot approach, multiple skin punctures, and use of ultrasound.

to describe the impact of antithrombotic therapies on bleeding propensity.

Patients receiving antithrombotic therapy had a 60% increase in risk of bloody punctures during peripheral block implementation. This increase in risk was independent of assignment to the 'paused adequately long' or 'not paused adequately long' group by the treating anesthesiologist possibly reflecting the lack of clear timing guidelines for peripheral blocks. Since, according to this definition, no risk reduction by discontinuation became visible, the establishment of specific guidelines based on the available recommendations and risk assessments might be useful.^{7,8}

There was no detectable increase in odds for bloody punctures in neuraxial blocks in patients taking antithrombotic medications compared with those who did not, presumably because antithrombotics were paused per guidelines in 89% of patients. In the remaining patients in whom the neuraxial blockade was performed outside guideline recommendations, there was a slight increase in odds. It was non-significant, probably because sample size was small. Furthermore, our information about guideline compliance was only yes or no, and we had no information on when drugs were actually stopped. Because neuraxial bleeding complications are feared, it seems likely that most of the 11% of patients who did not meet guideline recommendations for pausing antithrombotics were only slightly out of compliance. Our results thus suggest that neuraxial anesthesia is safe in patients taking antithrombotics so long as the drugs are stopped per guidelines. Since we are referring to the German guidelines, we would like to compare the relevant points with the US guidelines. In our sample, the most often used anticoagulant drug was low-molecular-weight heparin (78%), the most common antiplatelet drug was low dose aspirin (maximum 100 mg, 7%), and there were 7% combinations of at least two antithrombotics. In this respect, the recommendations in both guidelines are the same. Minor differences, which do not appear to be relevant to this analysis, exist for prophylactic doses of unfractionated heparin (Germany 4 hours, US 4–6 hours), for clopidogrel (Germany 7–10 days, US 5–7 days), and aspirin doses more than 100 milligrams which together accounted for less than 8% of the documented drugs.

Combined administration of drugs with various effects on blood clotting and possibly competing elimination pathways means that clinical effects are difficult to assess. Although current evidence suggests that there is no direct pharmacokinetic interaction between commonly used anticoagulant and antiplatelet drugs,^{30,31} we found that combined therapies roughly doubled

the odds for both peripheral and neuraxial blocks. Patients on combined therapies therefore appear to be at particular risk, possibly because the guidelines do not specify clear time intervals for these cases.

A limitation of the NET-RA registry is that it gathers anonymized primary data from various hospitals. The associated risk of under-reporting and inaccuracy is therefore hard to estimate but may be substantial. However, we assume that the rate of underreporting and inaccuracy does not differ across the study groups. Using routine data, we had to discard three-quarter of potentially eligible cases because of incomplete or implausible data which surely introduced a degree of selection bias. Since we focused on the main antithrombotic drug acting mechanisms, specific drugs may be underrepresented. Dosing could not be evaluated. Because there are no detailed guidelines for peripheral blocks, interruption of antithrombotic medications depends on anesthesiologists' judgements which may have influenced their assignment to the groups 'paused adequately long' and 'not paused adequately long'. Few patients surely appear more than once in the registry, but because data are anonymous we could not statistically adjust for repeated observations. During the long observation period of 13 years, there was presumably progress in medicine, techniques, and anesthesia methods making more recent cases more relevant.

Conclusions

In summary, bloody punctures during peripheral regional block insertion were more common in patients who took antithrombotic drugs. The increased odds was apparently not influenced by pausing antithrombotic medications, keeping in mind that there are no specific guidelines for peripheral blocks. For neuraxial punctures, the odds did not increase so long as antithrombotic medications were paused per guideline. Bloody punctures were about twice as common in patients who concurrently used at least two platelet and/or coagulation cascade inhibitors. We; therefore, conclude that patients taking antithrombotic drugs are at increased risk for bloody punctures, especially when treatments are not discontinued within recommended pre-procedure periods. Patients who take combined antiplatelet and/or anticoagulant drugs are at especially high risk. Guidelines for discontinuing antithrombotic treatments for neuraxial anesthesia appear to be effective, and should possibly be extended to peripheral blocks with a high risk of bleeding.

Acknowledgements We thank all hospital centers that are/were part of the net-ra registry and particularly those providing data for the current analysis: BG Unfallklinik Frankfurt am Main, Dr. med. Rolf Teßmann; BG Unfallklinik Murnau, Dr. med. Johannes Büttner; Charité CCM/CKV Berlin, Univ.-Prof. Dr. med. Claudia Spies; Christliches Klinikum Unna West, Dr. med. Wolf Armbruster; DIAKOVERE Friederikenstift und Henrietenstift Hannover, Prof. Dr. med. André Gottschalk; DIAKOVERE Annastift Hannover, PD Dr. med. Michael Przemec; DRK Kliniken Berlin Westend, Prof. Dr. med. Arnd Timmermann; Helios Klinikum Bad Saarow, Dr. med. Stefan Wirtz; Helios Klinikum Erfurt, Prof. Dr. med. Andreas Meier-Hellmann, and Dr. med. Gerald Burgard; Klinikum Memmingen, Prof. Dr. med. Lars Fischer; Knappschaftskrankenhaus Bochum, Prof. Dr. med. Michael Adamzik; Marienhospital Stuttgart, Prof. Dr. med. René Schmidt; OP-Ambulanz Schmerzzentrum Hannover, Dr. med. Frederic Böttcher; Orthopädische Universitätsklinik Frankfurt Friedrichsheim, Prof. Dr. med. Paul Kessler; Sana Klinik Bad Wildbad, Dr. med. Edgar Bauderer; Städtisches Klinikum Solingen, Prof. Dr. med. Thomas Standl; St. Marien-Krankenhaus Siegen, Prof. Dr. med. Werner Hering; Universitätsklinikum Carl Gustav Carus Dresden, Univ.-Prof. Dr. med. Thea Koch; Universitätsklinikum des Saarlandes Homburg/Saar, Univ.-Prof. Dr. med. Thomas Volk; UKE Hamburg, Univ.-Prof. Dr. med. Alwin E. Goetz; Universitätsklinikum Freiburg, Univ.-Prof. Dr. med. Hartmut Bürkle; Universitätsklinikum Jena, Prof. Dr. med. Konrad Reinhart; Universitätsklinikum Marburg (UKGM), Univ.-Prof. Dr. med. Hinnerk F. W. Wulf; Universitäts- und Rehabilitationskliniken Ulm (RKU), Dr. med. Jörg Winkelmann; Universitätsklinikum Würzburg, Univ.-Prof. Dr. med. Peter Kranke. For further information visit www.net-ra.eu

Contributors CK and TV contributed to planning, designing, and conducting the study, data analysis, drafting, revising, and submitting the manuscript. CK and TV act as guarantor. CAG and GW contributed to conducting the study, data analysis, interpretation and revising the manuscript. DIS contributed to the data analysis, drafting, and revising the manuscript.

Funding Support for the study was provided solely from institutional/hospital/departmental sources. The Network for Safety in Regional Anesthesia and Acute Pain Therapy is supported by the Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (N/A) and Berufsverband Deutscher Anästhesisten e.V. (N/A)

Competing interests DIS is a consultant for Pacira and his department conducts funded research for the company. Thomas Volk received honoraria for lectures from CSL Behring and Pajunk. CK, CAG and GW declare no competing interests.

Patient consent for publication Not applicable.

Ethics approval Approval for this retrospective cohort study was provided by the Ethics Committee of the Saarland Medical Chamber, Saarbrücken, Germany (Chairperson Prof. Dr. U. Grundmann) on April 15, 2020 (identification no. 75/20). Written consent was waived as the registry data are completely anonymous (regularly proof of protection of data privacy, Saarland commissioner, March 12, 2014).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iD

Christine Kubulus <http://orcid.org/0000-0003-0981-074X>

REFERENCES

- Horlocker TT, Vandermeulen E, Kopp SL, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of regional anesthesia and pain medicine evidence-based guidelines (fourth edition). *Reg Anesth Pain Med* 2018;43:263–309.
- Gogarten W, Vandermeulen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2010;27:999–1015.
- Kietaibl S, Ferrandis R, Godier A, et al. Regional anaesthesia in patients on antithrombotic drugs: joint ESAIC/ESRA guidelines. *Eur J Anaesthesiol* 2022;39:100–32.
- Waurick KR, Aken H.; Van, Kessler H., et al. Regional anaesthesia and thromboembolism prophylaxis/anticoagulation. third revised recommendations of the German Society of anaesthesiology and intensive care medicine. *Anästhesie und Intensivmedizin* 2014;55:464–92.
- Weller RS, Gerancher JC, Crews JC, et al. Extensive retroperitoneal hematoma without neurologic deficit in two patients who underwent lumbar plexus block and were later anticoagulated. *Anesthesiology* 2003;98:581–5.
- Aveline C, Bonnet F. Delayed retroperitoneal haematoma after failed lumbar plexus block. *Br J Anaesth* 2004;93:589–91.
- Joubert F, Gillois P, Bouaziz H, et al. Bleeding complications following peripheral regional anaesthesia in patients treated with anticoagulants or antiplatelet agents: a systematic review. *Anaesth Crit Care Pain Med* 2019;38:507–16.
- Tsui BCH, Kirkham K, Kwofie MK, et al. Practice Advisory on the bleeding risks for peripheral nerve and interfascial plane blockade: evidence review and expert consensus. *Can J Anaesth* 2019;66:1356–84.
- Bos EME, Haumann J, de Quelerij M, et al. Haematoma and abscess after neuraxial anaesthesia: a review of 647 cases. *Br J Anaesth* 2018;120:693–704.
- Bomberg H, Huth A, Wagenpfeil S, et al. Psoas versus femoral blocks: a Registry analysis of risks and benefits. *Reg Anesth Pain Med* 2017;42:719–24.
- Anipindi S, Ibrahim N. Epidural haematoma causing paraplegia in a patient with ankylosing spondylitis: a case report. *Anesth Pain Med* 2017;7:e43873.
- Lewis SR, Price A, Walker KJ, et al. Ultrasound guidance for upper and lower limb blocks. *Cochrane Database Syst Rev* 2015:CD006459.
- Munirama S, McLeod G. A systematic review and meta-analysis of ultrasound versus electrical stimulation for peripheral nerve location and blockade. *Anaesthesia* 2015;70:1084–91.
- Schnabel A, Meyer-Frießem CH, Zahn PK, et al. Ultrasound compared with nerve stimulation guidance for peripheral nerve catheter placement: a meta-analysis of randomized controlled trials. *Br J Anaesth* 2013;111:564–72.
- Kubulus C, Schmitt K, Albert N, et al. Awake, sedated or anaesthetised for regional anaesthesia block placements?: a retrospective registry analysis of acute complications and patient satisfaction in adults. *Eur J Anaesthesiol* 2016;33:715–24.
- Benchimol EI, Smeeth L, Guttman A, et al. The reporting of studies conducted using observational Routinely-collected health data (record) statement. *PLoS Med* 2015;12:e1001885.
- Volk T, Engelhardt L, Spies C, et al. [A German network for regional anaesthesia of the scientific working group regional anaesthesia within DGAI and BDA]. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2009;44:778–80.
- Bomberg H, Bayer I, Wagenpfeil S, et al. Prolonged catheter use and infection in regional anaesthesia: a retrospective registry analysis. *Anesthesiology* 2018;128:764–73.
- Bomberg H, Krotten D, Kubulus C, et al. Single-Dose antibiotic prophylaxis in regional anaesthesia: a retrospective registry analysis. *Anesthesiology* 2016;125:505–15.
- Buettner JB, Gogarten H., H.W.; Wulf. Thromboembolism prophylaxis and peripheral nerve blocks for regional anaesthesia. guideline of the German Society of anaesthesiology and intensive care medicine. *Anaesth Intensivmed* 2005;46:319–22.
- Horlocker TT, Wedel DJ, Schroeder DR, et al. Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anaesthesia. *Anesth Analg* 1995;80:303–9.
- Serebruany VL, Steinhilb SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. *Am J Cardiol* 2005;95:1218–22.
- Stuart EA. Matching methods for causal inference: a review and a look forward. *Stat Sci* 2010;25:1–21.
- Pöpping DM, Zahn PK, Van Aken HK, et al. Effectiveness and safety of postoperative pain management: a survey of 18 925 consecutive patients between 1998 and 2006 (2nd revision): a database analysis of prospectively raised data. *Br J Anaesth* 2008;101:832–40.
- Osaka Y, Yamashita M. Intervertebral epidural anaesthesia in 2,050 infants and children using the drip and tube method. *Reg Anesth Pain Med* 2003;28:103–7.
- Bomberg H, Paquet N, Huth A, et al. Epidural needle insertion: A large registry analysis. *Anaesthesist* 2018;67:922–30.
- Sites BD, Taenzer AH, Herrick MD, et al. Incidence of local anesthetic systemic toxicity and postoperative neurologic symptoms associated with 12,668 ultrasound-guided nerve blocks: an analysis from a prospective clinical Registry. *Reg Anesth Pain Med* 2012;37:478–82.
- Aliste J, Layera S, Bravo D, et al. Randomized comparison between pericapsular nerve group (PENG) block and suprainguinal fascia iliaca block for total hip arthroplasty. *Reg Anesth Pain Med* 2021;46:874–8.
- Arzola C, Balki M, Gleicher Y, et al. Comparison of ultrasound-assistance versus traditional palpation method for placement of thoracic epidural catheters: a randomized controlled trial. *Reg Anesth Pain Med* 2022;47:571–2.
- Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin. *J Clin Pharmacol* 2006;46:981–90.
- Valina C, Bömicke T, Abdelrazek S, et al. Pharmacodynamic safety of clopidogrel monotherapy in patients under oral anticoagulation with a vitamin K antagonist undergoing coronary stent implantation. *Platelets* 2019;30:714–9.

Supplement 1: Demographic and procedural data before and after matching

a) all regional anesthetic procedures	before matching			after matching		
	with thrombo-prophylaxis (n=21,009)	without thrombo-prophylaxis (n=44,805)	absolute standardized difference	with thrombo-prophylaxis (n=18,255)	without thrombo-prophylaxis (n=18,255)	absolute standardized difference
Demographic data						
Female sex	10,162 (48)	23,830 (53)	0.10	8,980 (49)	9,020 (49)	0.004
Age [yr]	64.0 (±15)	58.4 (±18)	0.33	63.0 (±16)	63.4 (±16)	0.03
BMI [kg/m ²]	28.2 (±6)	28.1 (±6)	0.01	28.1 (±6)	28.2 (±6)	0.02
ASA 1	1,475 (7)	5,931 (13)	0.20	1,458 (8)	1,384 (8)	0.02
ASA 2	7,900 (38)	21,938 (49)	0.22	7,469 (42)	7,312 (40)	0.02
ASA 3	10,897 (52)	16,349 (37)	0.22	8,783 (48)	9,082 (50)	0.03
ASA ≥4	737 (4)	587 (1)	0.19	545 (3)	477 (3)	0.02
Year of surgery	2012 (±3)	2014 (±3)	0.79	2012 (±3)	2012 (±3)	0.05
Comorbidities						
Renal insufficiency*	5,715 (27)	7,244 (16)	0.27	4,526 (25)	4,560 (25)	0.004
Technical data						
Peripheral puncture site	9,386 (45)	25,299 (57)	0.24	8,484 (56)	8,414 (56)	0.01
Neuraxial puncture site	11,623 (55)	19,506 (44)	0.22	9,771 (54)	9,841 (54)	0.01
Awake during block placement	9,915 (47)	17,949 (40)	0.14	8,415 (46)	8,501 (44)	0.01
Sedated or general anesthesia	11,094 (53)	26,856 (60)	0.14	9,840 (55)	9,754 (56)	0.01
Single shot	3,792 (18)	10,807 (24)	0.15	3,477 (19)	3,379 (19)	0.01
Catheter	17,217 (82)	33,998 (76)	0.15	14,778 (81)	14,876 (81)	0.01
Use of ultrasound	4,221 (20)	15,682 (35)	0.34	4,056 (22)	4,006 (22)	0.01
Multiple skin puncture	3,797 (18)	5,742 (13)	0.14	3,147 (17)	3,165 (17)	0.01
Antithrombotic therapy						
Paused per guideline	17,374 (87)	-	-	-	-	-
Not paused per guideline	2,574 (13)	-	-	-	-	-
Antiplatelet agent	1,643 (8)	-	-	-	-	-
Anticoagulant agent	17,538 (84)	-	-	-	-	-
Combined therapy	1,809 (9)	-	-	-	-	-
Other	6 (0.03)	-	-	-	-	-
Bloody tap	626 (3.0)	909 (2.0)	0.06	517 (2.8)	436 (2.4)	0.03

b) peripheral blocks	before matching			after matching		
	with thrombo- prophylaxis (n=9,386)	without thrombo- prophylaxis (n= 25,299)	absolute standardized difference	with thrombo- prophylaxis (n=8,220)	without thrombo- prophylaxis (n=8,220)	absolute standardized difference
Demographic data						
Female sex	4,799 (51)	13,441 (53)	0.04	4,223 (51)	4,298 (52)	0.02
Age [yr]	63.3 (±16)	57.2 (±18)	0.35	62.2 (±16)	62.8 (±16)	0.03
BMI [kg/m ²]	28.8 (±6)	28.4 (±6)	0.07	28.7 (±6)	28.9 (±6)	0.03
ASA 1	796 (9)	3,813 (15)	0.21	785 (10)	779 (10)	0.003
ASA 2	3,345 (36)	12,958 (51)	0.32	3,272 (40)	3,072 (37)	0.05
ASA 3	4,862 (52)	8,249 (33)	0.30	3,908 (48)	4,132 (50)	0.05
ASA ≥4	383 (4)	279 (0.1)	0.19	255 (3)	237 (3)	0.01
Year of surgery	2011 (±3)	2014 (±3)	0.79	2012 (±3)	2012 (±3)	0.05
Comorbidities						
Renal insufficiency*	2,745 (29)	3,815 (15)	0.34	2,147 (26)	2,194 (27)	0.05
Technical data						
Awake during block placement	2,644 (28)	6,841 (27)	0.03	2,292 (28)	2,358 (28)	0.02
Sedated or general anesthesia	6,742 (72)	18,458 (73)	0.03	5,928 (72)	5,862 (72)	0.02
Single shot	2,851 (30)	8,139 (32)	0.04	2,567 (31)	2,451 (30)	0.37
Catheter	6,535 (70)	17,160 (68)	0.04	5,653 (69)	5,769 (70)	0.37
Use of ultrasound	4,049 (43)	15,101 (60)	0.34	3,816 (46)	3,836 (47)	0.74
Multiple skin puncture	842 (9)	1,547 (6)	0.11	696 (9)	708 (9)	0.09
Antithrombotic therapy						
Paused adequately long	7,502 (85)	-	-	-	-	-
Not paused adequately long	1,330 (15)	-	-	-	-	-
Antiplatelet agent	855 (9)	-	-	-	-	-
Anticoagulant agent	7,667 (82)	-	-	-	-	-
Combined therapy	852 (9)	-	-	-	-	-
Other	5 (0.05)	-	-	-	-	-
Bloody tap	277 (3.0)	318 (1.3)	0.12	228 (2.8)	153 (1.9)	0.06

c) neuraxial blocks	before matching			after matching		
	with thrombo- prophylaxis (n= 11,623)	without thrombo- prophylaxis (n= 19,506)	absolute standardized difference	with thrombo- prophylaxis (n=9,852)	without thrombo- prophylaxis (n=9,852)	absolute standardized difference
Demographic data						
Female sex	5,363 (46)	10,389 (53)	0.14	4,674 (47)	4,666 (47)	0.002
Age [yr]	64.6 (±15)	59.8 (±18)	0.29	63.7 (±15)	64.0 (±15)	0.02
BMI [kg/m ²]	27.6 (±6)	27.7 (±6)	0.01	27.6 (±6)	27.7 (±6)	0.01
ASA 1	679 (6)	2,118 (11)	0.19	657 (7)	605 (6)	0.02
ASA 2	4,555 (39)	8,980 (46)	0.01	4,140 (42)	4,121 (42)	0.004
ASA 3	6,035 (52)	8,100 (42)	0.15	4,798 (49)	4,890 (50)	0.02
ASA ≥4	354 (3)	308 (1.6)	0.09	257 (3)	236 (2)	0.01
Year of surgery	2011 (±3)	2014 (±3)	0.75	2012 (±3)	2012 (±3)	0.06
Comorbidities						
Renal insufficiency*	2,970 (26)	3,429 (18)	0.23	2,350 (24)	2340 (24)	0.002
Technical data						
Awake during block placement	7,271 (63)	11,108 (57)	0.12	6,107 (62)	6,077 (62)	0.006
Sedated or general anesthesia	4,352 (37)	8,398 (43)	0.12	3,745 (38)	3,775 (38)	0.006
Single shot	941 (8)	2,668 (14)	0.18	859 (9)	869 (9)	0.004
Catheter	10,682 (92)	16,838 (86)	0.18	8,998 (91)	8,983 (91)	0.004
Use of ultrasound	172 (2)	581 (3)	0.10	167 (2)	163 (2)	0.003
Multiple skin puncture	2,955 (24)	4,195 (22)	0.09	2,431 (25)	2,432 (25)	0.000
Antithrombotic therapy						
Paused per guideline	9,872 (89)	-	-	-	-	-
Not paused per guideline	1,244 (11)	-	-	-	-	-
Antiplatelet agent	788 (7)	-	-	-	-	-
Anticoagulant agent	9,871 (85)	-	-	-	-	-
Combined therapy	957 (8)	-	-	-	-	-
Other	1 (0.01)	-	-	-	-	-
Bloody tap	349 (3.0)	591 (3.0)	0.00	288 (2.9)	285 (2.9)	0.002

Supplement 1a-c. Continuous variables are given as mean (\pm SD) and categorical variables as number (%). Standardized differences were calculated as differences in means or proportions (anticoagulated minus not anticoagulated) divided by the pooled SD and given as absolute values. Propensity score matching was based on all potential confounding variables. ASA=American Society of Anesthesiologists (Physical Status Classification System). *dialysis or CKD EPI < 60ml/min/1.73m²

Supplement 2: Risk factors for a bloody puncture during regional anesthesia procedures

Risk of bloody tap – all procedures	multivariate regression before matching		multivariate regression after matching	
	adjusted OR (95% CI)	P	adjusted OR (95% CI)	P
Antithrombotic therapy	1.16 (1.04-1.30)	0.011	1.18 (1.04-1.35)	0.013
Female sex	1.17 (1.05-1.30)	0.003	1.19 (1.04-1.35)	0.013
Age (yr)	1.00 (1.00-1.01)	0.616	1.00 (1.00-1.01)	0.062
BMI [kg/m ²]	1.01 (1.00-1.02)	0.008	1.02 (1.01-1.03)	<0.001
ASA 2	0.71 (0.60-0.85)	<0.001	0.62 (0.48-0.81)	<0.001
ASA 3	0.99 (0.83-1.19)	0.931	0.91 (0.70-1.20)	0.509
ASA ≥4	0.98 (0.67-1.45)	0.933	0.74 (0.45-1.23)	0.245
Renal insufficiency*	1.14 (1.01-1.30)	0.041	1.15 (0.98-1.35)	0.084
Neuraxial vs peripheral punctures	1.46 (1.29-1.66)	<0.001	1.21 (1.03-1.42)	0.018
Sedation or GA vs awake	2.65 (2.35-2.99)	<0.001	2.29 (1.97-2.65)	<0.001
Catheter vs single shot	0.62 (0.54-0.70)	<0.001	0.55 (0.47-0.64)	<0.001
No use of ultrasound	2.29 (1.92-2.73)	<0.001	2.23 (1.77-2.81)	<0.001
Multiple skin puncture	3.52 (3.15-3.94)	<0.001	3.23 (2.81-3.71)	<0.001
Year of surgery	0.97 (0.95-0.99)	<0.001	0.97 (0.94-0.99)	0.004
Risk of bloody tap – peripheral punctures				
Antithrombotic therapy	1.60 (1.33-1.93)	<0.001	1.48 (1.19-1.82)	<0.001
Female sex	0.99 (0.83-1.17)	0.890	1.06 (0.86-1.32)	0.583
Age (yr)	1.00 (1.00-1.01)	0.236	1.00 (1.00-1.01)	0.348
BMI [kg/m ²]	1.01 (0.99-1.02)	0.232	1.01 (1.00-1.03)	0.094
ASA 2	0.85 (0.65-1.11)	0.225	0.59 (0.40-0.86)	0.006
ASA 3	1.23 (0.95-1.60)	0.116	0.99 (0.66-1.48)	0.946
ASA ≥4	1.13 (0.61-2.13)	0.694	0.55 (0.22-1.38)	0.205
Renal insufficiency*	1.03 (0.83-1.28)	0.807	0.95 (0.73-1.24)	0.711
Sedation or GA vs awake	1.76 (1.42-2.20)	<0.001	1.87 (1.42-2.46)	<0.001
Catheter vs single shot	0.62 (0.52-0.74)	<0.001	0.62 (0.50-0.78)	<0.001
No use of ultrasound	2.15 (1.78-2.60)	<0.001	2.25 (1.76-2.88)	<0.001
Multiple skin puncture	6.32 (5.27-7.57)	<0.001	6.11 (4.89-7.63)	<0.001
Year of surgery	0.95 (0.92-0.98)	0.001	0.96 (0.92-1.00)	0.047
Risk of bloody tap – neuraxial punctures				
Antithrombotic therapy	0.95 (0.82-1.10)	0.523	1.00 (0.85-1.18)	0.994
Female sex	1.27 (1.11-1.45)	0.001	1.21 (1.02-1.43)	0.030
Age (yr)	1.00 (1.00-1.00)	0.807	1.00 (1.00-1.01)	0.243
BMI [kg/m ²]	1.01 (1.00-1.02)	0.023	1.02 (1.00-1.03)	0.013
ASA 2	0.68 (0.53-0.86)	0.001	0.72 (0.49-1.05)	0.089
ASA 3	0.92 (0.73-1.17)	0.501	1.00 (0.68-1.47)	0.988
ASA ≥4	0.95 (0.58-1.54)	0.827	0.92 (0.48-1.78)	0.815
Renal insufficiency*	1.18 (1.01-1.39)	0.039	1.22 (1.00-1.50)	0.049
Sedation or GA vs awake	2.90 (2.52-3.35)	<0.001	2.41 (2.03-2.87)	<0.001
Catheter vs single shot	0.66 (0.56-0.79)	<0.001	0.56 (0.44-0.71)	<0.001
No use of ultrasound	1.55 (0.93-2.56)	0.090	1.27 (0.62-2.58)	0.516
Multiple skin puncture	2.69 (2.34-3.08)	<0.001	2.48 (2.09-2.94)	<0.001
Year of surgery	0.98 (0.96-1.00)	0.116	0.97 (0.95-1.00)	0.059

Supplement 2. OR=Odds Ratio, adjusted for antithrombotic therapy, sex, age, BMI, ASA, renal insufficiency, puncture site, state of consciousness during block implementation, catheter or single shot, use of ultrasound, multiple skin puncture, and year of surgery. CI= Confidence interval. ASA=American Society of Anesthesiologists (Physical Status Classification System). GA=General anesthesia. *dialysis or CKD EPI < 60ml/min/1.73m². Propensity score matching considered all potential confounding variables.